{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:06:21Z","timestamp":1791648381987,"version":"4.3.4"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T00:00:00Z","timestamp":1659916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T00:00:00Z","timestamp":1659916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Schering Plough, Mexico"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess the efficacy and safety of infliximab versus placebo in the treatment of patients with juvenile-onset spondyloarthritis (JoSpA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Phase III, randomized, double-blind, placebo-controlled trial of 12 weeks that included patients \u2264 18 years old with JoSpA not responding to nonsteroidal anti-inflammatory drugs, sulfasalazine, or methotrexate. Patients were randomly assigned 1:1 to the infusion of infliximab 5mg\/kg or placebo; completers entered then an open-label extension (OLE) period of 42 weeks. The primary endpoint was the number of active joints. Secondary outcomes included the assessment of disease activity, tender entheses, spinal mobility, serum C-reactive protein (CRP), the Bath Ankylosing Spondylitis Disease Activity and Functional Index, and the Childhood Health Assessment Questionnaire (CHAQ).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We randomized 12 patients to infliximab and 14 to placebo. No significant differences were found between groups at baseline. At week 12, the mean number of active joints was 1.4 (SD 2.4) in the infliximab group and 4.1 (SD 3.0) in the placebo group (<jats:italic>p<\/jats:italic>= 0.0002). A repeated-measures mixed model analysis that included all endpoints in the study demonstrated sustained favourable outcomes of infliximab for active joints, tender joints, swollen joints, and tender enthesis counts, as well as for CHAQ and CRP (<jats:italic>p<\/jats:italic>&lt; 0.01). Adverse events were more frequent in the infliximab group, including infections and infusion reactions, but none of them was serious.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Infliximab is efficacious for patients with JoSpA with an inadequate response to conventional treatment. No serious adverse events with the use of infliximab were observed.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13075-022-02877-9","type":"journal-article","created":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T06:03:38Z","timestamp":1659938618000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["A randomized, double-blind, placebo-controlled 12-week trial of infliximab in patients with juvenile-onset spondyloarthritis"],"prefix":"10.1186","volume":"24","author":[{"given":"Rub\u00e9n","family":"Burgos-Vargas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adalberto","family":"Loyola-Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Ramiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Reding-Bernal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Everardo","family":"Alvarez-Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janitzia","family":"V\u00e1zquez-Mellado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,8]]},"reference":[{"issue":"3","key":"2877_CR1","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S0889-857X(02)00033-9","volume":"28","author":"R Burgos-Vargas","year":"2002","unstructured":"Burgos-Vargas R. The juvenile-onset spondyloarthritides. Rheum Dis Clin N Am. 2002;28(3):531\u201360 vi.","journal-title":"Rheum Dis Clin N Am"},{"issue":"4","key":"2877_CR2","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0022-3476(82)80746-4","volume":"100","author":"JC Jacobs","year":"1982","unstructured":"Jacobs JC, Berdon WE, Johnston AD. HLA-B27-associated spondyloarthritis and enthesopathy in childhood: clinical, pathologic, and radiographic observations in 58 patients. J Pediatr. 1982;100(4):521\u20138.","journal-title":"J Pediatr"},{"issue":"9","key":"2877_CR3","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1002\/art.1780250902","volume":"25","author":"AM Rosenberg","year":"1982","unstructured":"Rosenberg AM, Petty RE. A syndrome of seronegative enthesopathy and arthropathy in children. Arthritis Rheum. 1982;25(9):1041\u20137.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2877_CR4","first-page":"192","volume":"16","author":"R Burgos-Vargas","year":"1989","unstructured":"Burgos-Vargas R, Clark P. Axial involvement in the seronegative enthesopathy and arthropathy syndrome and its progression to ankylosing spondylitis. J Rheumatol. 1989;16(2):192\u20137.","journal-title":"J Rheumatol"},{"issue":"8","key":"2877_CR5","first-page":"1282","volume":"19","author":"DA Cabral","year":"1992","unstructured":"Cabral DA, Oen KG, Petty RE. SEA syndrome revisited: a longterm followup of children with a syndrome of seronegative enthesopathy and arthropathy. J Rheumatol. 1992;19(8):1282\u20135.","journal-title":"J Rheumatol"},{"issue":"6","key":"2877_CR6","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1002\/art.1780380618","volume":"38","author":"R Burgos-Vargas","year":"1995","unstructured":"Burgos-Vargas R, V\u00e1zquez-Mellado J. The early clinical recognition of juvenile-onset ankylosing spondylitis and its differentiation from juvenile rheumatoid arthritis. Arthritis Rheum. 1995;38(6):835\u201344.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"2877_CR7","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S van der Linden","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361\u20138.","journal-title":"Arthritis Rheum"},{"key":"2877_CR8","doi-asserted-by":"publisher","first-page":"15013","DOI":"10.1038\/nrdp.2015.13","volume":"1","author":"J Sieper","year":"2015","unstructured":"Sieper J, Braun J, Dougados M, Baeten D. Axial spondyloarthritis. Nat Rev Dis Primers. 2015;1:15013.","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"2877_CR9","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1136\/ard.2003.011247","volume":"63","author":"M Rudwaleit","year":"2004","unstructured":"Rudwaleit M, van der Heijde D, Khan MA, Braun J, Sieper J. How to diagnose axial spondyloarthritis early. Ann Rheum Dis. 2004;63(5):535\u201343.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"2877_CR10","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1136\/annrheumdis-2015-208642","volume":"75","author":"RG Lambert","year":"2016","unstructured":"Lambert RG, Bakker PA, van der Heijde D, Weber U, Rudwaleit M, Hermann KG, et al. Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group. Ann Rheum Dis. 2016;75(11):1958\u201363.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2877_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2020.101628","volume":"34","author":"K Aouad","year":"2020","unstructured":"Aouad K, Maksymowych WP, Baraliakos X, Ziade N. Update of imaging in the diagnosis and management of axial spondyloarthritis. Best Pract Res Clin Rheumatol. 2020;34(6):101628.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"2","key":"2877_CR12","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390\u20132.","journal-title":"J Rheumatol"},{"issue":"10","key":"2877_CR13","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1136\/ard.61.10.941","volume":"61","author":"R Burgos-Vargas","year":"2002","unstructured":"Burgos-Vargas R, V\u00e1zquez-Mellado J, Pacheco-Tena C, Hern\u00e1ndez-Gardu\u00f1o A, Goycochea-Robles MV. A 26 week randomised, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies. Ann Rheum Dis. 2002;61(10):941\u20132.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2877_CR14","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1136\/annrheumdis-2012-203046","volume":"73","author":"G Horneff","year":"2014","unstructured":"Horneff G, Burgos-Vargas R, Constantin T, Foeldvari I, Vojinovic J, Chasnyk VG, et al. Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study. Ann Rheum Dis. 2014;73(6):1114\u201322.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"2877_CR15","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1002\/art.39145","volume":"67","author":"G Horneff","year":"2015","unstructured":"Horneff G, Foeldvari I, Minden K, Trauzeddel R, K\u00fcmmerle-Deschner JB, Tenbrock K, et al. Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study. Arthritis Rheum. 2015;67(8):2240\u20139.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"2877_CR16","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1002\/acr.22657","volume":"67","author":"R Burgos-Vargas","year":"2015","unstructured":"Burgos-Vargas R, Tse SM, Horneff G, Pangan AL, Kalabic J, Goss S, et al. A randomized, double-blind, placebo-controlled multicenter study of adalimumab in pediatric patients with enthesitis-related arthritis. Arthritis Care Res. 2015;67(11):1503\u201312.","journal-title":"Arthritis Care Res"},{"issue":"5","key":"2877_CR17","doi-asserted-by":"publisher","first-page":"R230","DOI":"10.1186\/ar4072","volume":"14","author":"G Horneff","year":"2012","unstructured":"Horneff G, Fitter S, Foeldvari I, Minden K, Kuemmerle-Deschner J, Tzaribacev N, et al. Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement. Arthritis Res Ther. 2012;14(5):R230.","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"2877_CR18","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1002\/art.22838","volume":"56","author":"N Ruperto","year":"2007","unstructured":"Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007;56(9):3096\u2013106.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"2877_CR19","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1136\/ard.2009.100354","volume":"69","author":"N Ruperto","year":"2010","unstructured":"Ruperto N, Lovell DJ, Cuttica R, Woo P, Meiorin S, Wouters C, et al. Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis. 2010;69(4):718\u201322.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2877_CR20","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1002\/art.1780341003","volume":"34","author":"M Dougados","year":"1991","unstructured":"Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum. 1991;34(10):1218\u201327.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"2877_CR21","first-page":"379","volume":"50","author":"AM Prieur","year":"1993","unstructured":"Prieur AM, Listrat V, Dougados M, Amor B. Criteria for classification of spondylarthropathies in children. Arch Fr Pediatr. 1993;50(5):379\u201385.","journal-title":"Arch Fr Pediatr"},{"issue":"2","key":"2877_CR22","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/art.1780290216","volume":"29","author":"JT Cassidy","year":"1986","unstructured":"Cassidy JT, Levinson JE, Bass JC, Baum J, Brewer EJ, Fink CW, et al. A study of classification criteria for a diagnosis of juvenile rheumatoid arthritis. Arthritis Rheum. 1986;29(2):274\u201381.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"2877_CR23","first-page":"451","volume":"21","author":"MH Cardiel","year":"2003","unstructured":"Cardiel MH, Londo\u00f1o JD, Guti\u00e9rrez E, Pacheco-Tena C, V\u00e1zquez-Mellado J, Burgos-Vargas R. Translation, cross-cultural adaptation, and validation of the Bath Ankylosing Spondylitis Functional Index (BASFI), the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Dougados Functional Index (DFI) in a Spanish speaking population with spondyloarthropathies. Clin Exp Rheumatol. 2003;21(4):451\u20138.","journal-title":"Clin Exp Rheumatol"},{"issue":"4 Suppl 23","key":"2877_CR24","first-page":"S106","volume":"19","author":"C Duarte","year":"2001","unstructured":"Duarte C, Ruperto N, Goycochea MV, Maldonado R, Beristain R, De Inocencio J, et al. The Mexican version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol. 2001;19(4 Suppl 23):S106\u201310.","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"2877_CR25","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","volume":"40","author":"EH Giannini","year":"1997","unstructured":"Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40(7):1202\u20139.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"2877_CR26","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F","volume":"44","author":"JJ Anderson","year":"2001","unstructured":"Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum. 2001;44(8):1876\u201386.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"2877_CR27","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1136\/ard.2003.016717","volume":"63","author":"J Brandt","year":"2004","unstructured":"Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J. Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Ann Rheum Dis. 2004;63(11):1438\u201344.","journal-title":"Ann Rheum Dis"},{"key":"2877_CR28","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1471-2288-1-6","volume":"1","author":"AJ Vickers","year":"2001","unstructured":"Vickers AJ. The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: a simulation study. BMC Med Res Methodol. 2001;1:6.","journal-title":"BMC Med Res Methodol"},{"key":"2877_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.680916","volume":"8","author":"JA Smith","year":"2021","unstructured":"Smith JA, Burgos-Vargas R. Outcomes in juvenile-onset spondyloarthritis. Front Med (Lausanne). 2021;8:680916.","journal-title":"Front Med (Lausanne)"},{"issue":"11","key":"2877_CR30","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.3899\/jrheum.130542","volume":"40","author":"DR Jadon","year":"2013","unstructured":"Jadon DR, Ramanan AV, Sengupta R. Juvenile versus adult-onset ankylosing spondylitis -- clinical, radiographic, and social outcomes. a systematic review. J Rheumatol. 2013;40(11):1797\u2013805.","journal-title":"J Rheumatol"},{"issue":"4","key":"2877_CR31","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1002\/art.10146","volume":"46","author":"B Flat\u00f8","year":"2002","unstructured":"Flat\u00f8 B, Smerdel A, Johnston V, Lien G, Dale K, Vinje O, et al. The influence of patient characteristics, disease variables, and HLA alleles on the development of radiographically evident sacroiliitis in juvenile idiopathic arthritis. Arthritis Rheum. 2002;46(4):986\u201394.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"2877_CR32","first-page":"1382","volume":"33","author":"AM Selvaag","year":"2006","unstructured":"Selvaag AM, Flat\u00f8 B, Dale K, Lien G, Vinje O, Smerdel-Ramoya A, et al. Radiographic and clinical outcome in early juvenile rheumatoid arthritis and juvenile spondyloarthropathy: a 3-year prospective study. J Rheumatol. 2006;33(7):1382\u201391.","journal-title":"J Rheumatol"},{"issue":"9","key":"2877_CR33","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1002\/art.10444","volume":"46","author":"K Minden","year":"2002","unstructured":"Minden K, Niewerth M, Listing J, Biedermann T, Bollow M, Sch\u00f6ntube M, et al. Long-term outcome in patients with juvenile idiopathic arthritis. Arthritis Rheum. 2002;46(9):2392\u2013401.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2877_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000366","volume":"3","author":"A Wei\u00df","year":"2017","unstructured":"Wei\u00df A, Minden K, Listing J, Foeldvari I, Sieper J, Rudwaleit M. Course of patients with juvenile spondyloarthritis during 4\u00a0years of observation, juvenile part of GESPIC. RMD Open. 2017;3(1):e000366.","journal-title":"RMD Open"},{"issue":"9","key":"2877_CR35","first-page":"2256","volume":"27","author":"K Minden","year":"2000","unstructured":"Minden K, Kiessling U, Listing J, Niewerth M, D\u00f6ring E, Meincke J, et al. Prognosis of patients with juvenile chronic arthritis and juvenile spondyloarthropathy. J Rheumatol. 2000;27(9):2256\u201363.","journal-title":"J Rheumatol"},{"issue":"2","key":"2877_CR36","first-page":"366","volume":"25","author":"B Flat\u00f8","year":"1998","unstructured":"Flat\u00f8 B, Aasland A, Vinje O, F\u00f8rre O. Outcome and predictive factors in juvenile rheumatoid arthritis and juvenile spondyloarthropathy. J Rheumatol. 1998;25(2):366\u201375.","journal-title":"J Rheumatol"},{"issue":"6","key":"2877_CR37","first-page":"922","volume":"25","author":"C Duarte-Salazar","year":"2007","unstructured":"Duarte-Salazar C, Guzm\u00e1n-V\u00e1zquez S, Soto-Molina H, Ch\u00e1idez-Rosales P, Ilizaliturri-S\u00e1nchez V, Nieves-Silva J, et al. Disability impact on quality of life in Mexican adults with juvenile idiopathic arthritis and juvenile ankylosing spondylitis. Clin Exp Rheumatol. 2007;25(6):922\u20137.","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"2877_CR38","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.3899\/jrheum.120642","volume":"39","author":"PF Weiss","year":"2012","unstructured":"Weiss PF, Beukelman T, Schanberg LE, Kimura Y, Colbert RA, Investigators CR. Enthesitis-related arthritis is associated with higher pain intensity and poorer health status in comparison with other categories of juvenile idiopathic arthritis: the Childhood Arthritis and Rheumatology Research Alliance Registry. J Rheumatol. 2012;39(12):2341\u201351.","journal-title":"J Rheumatol"},{"key":"2877_CR39","doi-asserted-by":"crossref","unstructured":"Rumsey DG, Lougee A, Matsouaka R, Collier DH, Schanberg LE, Schenfeld J, et al. Juvenile Spondyloarthritis in the CARRA Registry: high biologic use, low prevalence of HLA-B27, and equal sex representation in sacroiliitis. Arthritis Care Res. 2020.","DOI":"10.1002\/acr.24537"},{"issue":"9636","key":"2877_CR40","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","volume":"372","author":"N Ruperto","year":"2008","unstructured":"Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-P\u00e9rez N, Silva CA, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372(9636):383\u201391.","journal-title":"Lancet."},{"issue":"11","key":"2877_CR41","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1002\/art.27670","volume":"62","author":"N Ruperto","year":"2010","unstructured":"Ruperto N, Giannini EH, Pistorio A, Brunner HI, Martini A, Lovell DJ. Is it time to move to active comparator trials in juvenile idiopathic arthritis?: a review of current study designs. Arthritis Rheum. 2010;62(11):3131\u20139.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"2877_CR42","first-page":"919","volume":"23","author":"EH Giannini","year":"1996","unstructured":"Giannini EH, Lovell DJ, Silverman ED, Sundel RP, Tague BL, Ruperto N. Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis: a phase I\/II study. Pediatric Rheumatology Collaborative Study Group. J Rheumatol. 1996;23(5):919\u201324.","journal-title":"J Rheumatol"},{"issue":"7","key":"2877_CR43","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/acr.20497","volume":"63","author":"CA Wallace","year":"2011","unstructured":"Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N, Alliance CARR, et al. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res. 2011;63(7):929\u201336.","journal-title":"Arthritis Care Res"},{"issue":"1","key":"2877_CR44","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13075-019-1916-9","volume":"21","author":"I Foeldvari","year":"2019","unstructured":"Foeldvari I, Constantin T, Vojinovi\u0107 J, Horneff G, Chasnyk V, Dehoorne J, et al. Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial. Arthritis Res Ther. 2019;21(1):125.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"2877_CR45","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s13075-018-1780-z","volume":"20","author":"J Swart","year":"2018","unstructured":"Swart J, Giancane G, Horneff G, Magnusson B, Hofer M, Alexeeva \u0415, et al. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries. Arthritis Res Ther. 2018;20(1):285.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"2877_CR46","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13075-020-02167-2","volume":"22","author":"G Giancane","year":"2020","unstructured":"Giancane G, Swart JF, Castagnola E, Groll AH, Horneff G, Huppertz HI, et al. Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee. Arthritis Res Ther. 2020;22(1):71.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"2877_CR47","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00296-020-04774-3","volume":"41","author":"F Thiele","year":"2021","unstructured":"Thiele F, Klein A, Windschall D, Hospach A, Foeldvari I, Minden K, et al. Comparative risk of infections among real-world users of biologics for juvenile idiopathic arthritis: data from the German BIKER registry. Rheumatol Int. 2021;41(4):751\u201362.","journal-title":"Rheumatol Int"},{"issue":"1","key":"2877_CR48","first-page":"37","volume":"2","author":"A Klein","year":"2020","unstructured":"Klein A, Becker I, Minden K, Hospach A, Schwarz T, Foeldvari I, et al. Biologic therapies in polyarticular juvenile idiopathic arthritis. Comparison of long-term safety data from the German BIKER Registry. ACR Open. Rheumatol. 2020;2(1):37\u201347.","journal-title":"Rheumatol."},{"issue":"9","key":"2877_CR49","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1093\/rheumatology\/kez577","volume":"59","author":"A Klein","year":"2020","unstructured":"Klein A, Klotsche J, H\u00fcgle B, Minden K, Hospach A, Weller-Heinemann F, et al. Long-term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registry. Rheumatology (Oxford). 2020;59(9):2287\u201398.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"2877_CR50","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.3899\/jrheum.130133","volume":"40","author":"A Tambralli","year":"2013","unstructured":"Tambralli A, Beukelman T, Weiser P, Atkinson TP, Cron RQ, Stoll ML. High doses of infliximab in the management of juvenile idiopathic arthritis. J Rheumatol. 2013;40(10):1749\u201355.","journal-title":"J Rheumatol"},{"issue":"4","key":"2877_CR51","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/BOR.0000000000000619","volume":"31","author":"S Arepalli","year":"2019","unstructured":"Arepalli S, Rosenbaum JT. The use of biologics for uveitis associated with spondyloarthritis. Curr Opin Rheumatol. 2019;31(4):349\u201354.","journal-title":"Curr Opin Rheumatol"},{"issue":"12","key":"2877_CR52","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1136\/ard.2008.100826","volume":"68","author":"D van der Heijde","year":"2009","unstructured":"van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68(12):1811\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2877_CR53","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1136\/ard.2010.138594","volume":"70","author":"P Machado","year":"2011","unstructured":"Machado P, Landew\u00e9 R, Lie E, Kvien TK, Braun J, Baker D, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis. 2011;70(1):47\u201353.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"2877_CR54","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1093\/rheumatology\/key246","volume":"57","author":"A Zanwar","year":"2018","unstructured":"Zanwar A, Phatak S, Aggarwal A. Prospective validation of the Juvenile Spondyloarthritis Disease Activity Index in children with enthesitis-related arthritis. Rheumatology (Oxford). 2018;57(12):2167\u201371.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"2877_CR55","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/art.24516","volume":"61","author":"A Consolaro","year":"2009","unstructured":"Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61(5):658\u201366.","journal-title":"Arthritis Rheum"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02877-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-022-02877-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02877-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T11:10:50Z","timestamp":1700910650000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-022-02877-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,8]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2877"],"URL":"https:\/\/doi.org\/10.1186\/s13075-022-02877-9","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,8]]},"assertion":[{"value":"25 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Research and Ethics Review Board of the Hospital General de Mexico Dr. Eduardo Liceaga approved the conduction of this trial (Hospital General de Mexico Research Division Registry: HGM\/DIC\/02\/404-B\/02\/036). Patients, parents, or legal guardians and two witnesses were informed about the study and if accepted to participate signed an informed consent form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agree to the terms of the BioMed Central Copyright and License Agreement for the publication of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Rub\u00e9n Burgos Vargas received funding from Schering Plough, Mexico, to complete the data collection of this study. None of the other authors received any compensation from this or any other pharmaceutical company for the analysis or interpretation of the results.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"187"}}